Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPLORE: GT005 in geographic atrophy secondary to age-related macular degeneration
2019-003421-22Phase 2Unknown
- Sponsor
- Gyroscope Therapeutics
- Start
- Oct 2019
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of GT005 in age-related macular degeneration (AMD) (2 arms), sponsored by Gyroscope Therapeutics. Status: unknown.
02
Drugs
GT005
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2019-003421-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003421-22.